Abstract
Providing access to breakthrough cancer treatments and eradicating survival disparities from cancer in low-and-middle income countries poses a crucial public health challenge. It requires sustainable, targeted approaches that bolster health system capacity to provide the latest treatments while supporting patients in navigating socioeconomic barriers to care. The Max Foundation launched Max Access Solutions in 2017 to meet this public health need. Max Access Solutions is an end-to-end platform that ensures therapeutic and diagnostic products reach patients in need, while providing accompaniment services to patients and physicians through a global team of local program coordinators who understand the local healthcare context. Max Access Solutions and its predecessor, the Glivec International Patient Assistance Program (GIPAP), has successfully provided access to novel cancer treatments to more than 100,000 cancer patients in 75+ countries. In this article, we describe the development, structure, and potential future directions of the Max Access Solutions model.
